Effect of changes in metabolic enzymes and transporters on drug metabolism in the context of liver disease: Impact on pharmacokinetics and drug–drug interactions
British Journal of Clinical Pharmacology · 2024-04 · 90 (4) · 942-958
DOI: 10.1111/bcp.15990 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift British Journal of Clinical Pharmacology, online erschienen am 25.01.2024. Verfasst von Sara Armani und 5 weiteren Autor:innen. Beteiligte Einrichtung: CRS Clinical Research Services, Mannheim, Germany. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Organic Anion Transporters, Liver Diseases. Die Arbeit wurde bisher 70-mal zitiert (Crossref) und nennt 171 Literaturangaben. Gefördert von: CRS Clinical Research Services, Mannheim, Germany.
Abstract (Originalsprache)
Changes in the pharmacokinetic and resulting pharmacodynamic properties of drugs are common in many chronic liver diseases, leading to adverse effects, drug interactions and increased risk of over‐ or underdosing of medications. Structural and functional hepatic impairment can have major effects on drug metabolism and transport. This review summarizes research on the functional changes in phase I and II metabolic enzymes and in transport proteins in patients with metabolic diseases such as type 2 diabetes, metabolic dysfunction‐associated steatotic liver disease, metabolic dysfunction‐associated steatohepatitis and cirrhosis, providing a clinical perspective on how these changes affect drug uptake and metabolism. Generally, a decrease in expression and/or activity of many enzymes of the cytochrome P450 family (e.g. CYP2E1 and CYP3A4), and of influx and efflux transporters (e.g. organic anion‐transporting polypeptide [OATP]1B1, OATP2B1, OAT2 and bile salt export pump), has been recently documented in patients with liver disease. Decreased enzyme levels often correlate with increased severity of chronic liver disease. In subjects with hepatic impairment, there is potential for strong alterations of drug pharmacokinetics due to reduced absorption, increased volume of distribution, metabolism and extraction. Due to the altered pharmacokinetics, specific drug–drug interactions are also a potential issue to consider in patients with liver disease. Given the huge burden of liver disease in western societies, there is a need to improve awareness among all healthcare professionals and patients with liver disease to ensure appropriate drug prescriptions.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- CRS Clinical Research Services, Mannheim, Germany.
- Department of Internal Medicine and Hepatology, University Hospital, Würzburg, Germany.
- Department of Internal Medicine IV, University Hospital, Heidelberg, Germany.
- Department of Medicine, Washington University School of Medicine, St. Louis, Missouri, USA.
- Rickmansworth, Hertfordshire, UK.
ORCID-Profile: Sara Armani
Förderung
- CRS Clinical Research Services, Mannheim, Germany
Zitieren
APA
Armani, S., Geier, A., Forst, T., Merle, U., Alpers, D. H., & Lunnon, M. W. (2024). Effect of changes in metabolic enzymes and transporters on drug metabolism in the context of liver disease: Impact on pharmacokinetics and drug–drug interactions. British Journal of Clinical Pharmacology, 90(4), 942-958. https://doi.org/10.1111/bcp.15990
Vancouver
Armani S, Geier A, Forst T, Merle U, Alpers DH, Lunnon MW. Effect of changes in metabolic enzymes and transporters on drug metabolism in the context of liver disease: Impact on pharmacokinetics and drug–drug interactions. British Journal of Clinical Pharmacology. 2024;90(4):942-958. doi:10.1111/bcp.15990
BibTeX
@article{Armani2024,
author = {Armani, Sara and Geier, Andreas and Forst, Thomas and Merle, Uta and Alpers, David H and Lunnon, Martin W},
title = {Effect of changes in metabolic enzymes and transporters on drug metabolism in the context of liver disease: Impact on pharmacokinetics and drug–drug interactions},
journal = {British Journal of Clinical Pharmacology},
year = {2024},
volume = {90},
number = {4},
pages = {942--958},
doi = {10.1111/bcp.15990}
}
EUVIMED